Alnylam's Founding CEO John Maraganore To Exit The Company

In a surprise announcement, Alnylam Pharmaceuticals Inc's ALNY founding CEO John Maraganore will hand the reins to current president Yvonne Greenstreet at the end of the year.
The transition marks the end of a 20-year run as the founding CEO of the Company.
Maraganore will stay on through the first quarter as a consultant and take a seat on Alnylam's scientific advisory board.
Alnylam also reported Q3 sales of $187.6 million, +49% Y/Y, missing the consensus of $218.69 million. Product revenue increased 68% to $167 million.
Onpattro sales increased 6% to $120 million with 1,875 hATTR amyloidosis patients.
Givlaari sales increased 4% to $32 million and attained over 300 patients.
Oxlumo sales decreased 9% to 15 million, reflecting the transition of the initial bolus of commercial patients from monthly loading dose to quarterly maintenance dose regimens. It attained over 120 patients worldwide.
The Company posted an adjusted EPS loss of $(1.51), down from $(1.58) a year ago and better than the consensus of $(1.57).
Guidance: Alnylam reiterated FY21 product sales at $640 million - $665 million.
Price Action: ALNY shares are down 14.5% at $163.42 during the market session on the last check Thursday.

Earnings Calendar